statistiche ricercatore

Continente	#
NA - Nord America	1.143
AS - Asia	341
EU - Europa	241
SA - Sud America	74
AF - Africa	26
Continente sconosciuto - Info sul continente non disponibili	3
OC - Oceania	1
Totale	1.829

Nazione	#
US - Stati Uniti d'America	1.127
SG - Singapore	111
CN - Cina	105
BR - Brasile	67
RU - Federazione Russa	53
SE - Svezia	49
HK - Hong Kong	43
VN - Vietnam	34
DE - Germania	32
GB - Regno Unito	24
IT - Italia	19
FI - Finlandia	17
FR - Francia	17
CI - Costa d'Avorio	16
BD - Bangladesh	10
BE - Belgio	9
CA - Canada	9
IN - India	7
ID - Indonesia	5
LT - Lituania	5
MX - Messico	5
IQ - Iraq	4
JP - Giappone	4
EC - Ecuador	3
NL - Olanda	3
PL - Polonia	3
UA - Ucraina	3
UZ - Uzbekistan	3
AE - Emirati Arabi Uniti	2
CO - Colombia	2
ES - Italia	2
EU - Europa	2
JO - Giordania	2
KE - Kenya	2
PH - Filippine	2
PK - Pakistan	2
TN - Tunisia	2
TR - Turchia	2
ZA - Sudafrica	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AO - Angola	1
AU - Australia	1
BG - Bulgaria	1
CL - Cile	1
DO - Repubblica Dominicana	1
DZ - Algeria	1
ET - Etiopia	1
IE - Irlanda	1
KG - Kirghizistan	1
LK - Sri Lanka	1
MK - Macedonia	1
MZ - Mozambico	1
OM - Oman	1
PS - Palestinian Territory	1
QA - Qatar	1
RO - Romania	1
VC - Saint Vincent e Grenadine	1
VE - Venezuela	1
Totale	1.829

Nome	#
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study	193
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta	182
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort	180
A rare case of multiple sclerosis and McArdle disease	179
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients	179
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients	164
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy	160
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis	154
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study	150
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis	145
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis.	145
null	65
Totale	1.896

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	6	0	0	0	0	0	0	0	0	0	0	0	6
2021/2022	103	3	10	0	0	6	15	4	3	10	12	20	20
2022/2023	175	29	32	13	18	15	13	2	20	18	2	5	8
2023/2024	49	6	13	4	3	6	5	0	2	0	1	0	9
2024/2025	256	18	4	23	12	10	20	29	25	14	11	27	63
2025/2026	515	93	28	43	68	75	32	34	18	59	48	16	1
Totale													1.896